Search Results - "Hopps, Rachel"

Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion by Myers, Jacob A., Schirm, Dawn, Bendzick, Laura, Hopps, Rachel, Selleck, Carly, Hinderlie, Peter, Felices, Martin, Miller, Jeffrey S.

“…NK cell exhaustion is caused by chronic exposure to activating stimuli during viral infection, tumorigenesis, and prolonged cytokine treatment. Evidence…”
Get full text

Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation by Yang, Jianbo, Liao, Qianjin, Price, Matthew, Moriarity, Branden, Wolf, Natalie, Felices, Martin, Miller, Jeffrey S., Geller, Melissa A., Bendzick, Laura, Hopps, Rachel, Starr, Timothy K., O'Connor, Christine H., Tarullo, Sarah, Nelson, Andrew C., Turley, Eva, Wang, Jing, McCarthy, James B.

“…•Clinical –The studies are the first to identify CSPG4 as an oncoantigen which is associated with poor outcome in patients with ovarian cancer.•CSPG4…”
Get full text

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity by Kaminski, Michael F, Bendzick, Laura, Hopps, Rachel, Kauffman, Marissa, Kodal, Behiye, Soignier, Yvette, Hinderlie, Peter, Walker, Joshua T, Lenvik, Todd R, Geller, Melissa A, Miller, Jeffrey S, Felices, Martin

“…BackgroundThe tumor microenvironment contains stromal cells, including endothelial cells and fibroblasts, that aid tumor growth and impair immune cell…”
Get full text

Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer by Felices, Martin, Wesley, Erin, Bendzick, Laura E, Kodal, Behiye, Hopps, Rachel, Grzywacz, Bartosz, Hinderlie, Peter, Miller, Jeffrey S, Geller, Melissa A

“…Immune checkpoint blockade (ICB) has changed the standard of care for many patients with cancer, yet no ICB is approved for ovarian cancer. We hypothesized…”
Get more information

Abstract 2878: Mediating NK cell function against solid tumors, via targeting of tumor stroma, using a TEM8-targeting Tri-specific Killer Engager (TriKE®) by Felices, Martin, Kaminski, Michael, Hinderlie, Peter, Hopps, Rachel, Bendzick, Laura, Geller, Melissa, Miller, Jeffrey S.

“…Abstract Immunotherapies for solid tumors need to overcome barriers within the solid tumor microenvironment (TME), including stromal cells, cancer-associated…”
Get full text